Gulf International Bank UK Ltd decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 26.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 138,158 shares of the company's stock after selling 48,804 shares during the quarter. Johnson & Johnson accounts for approximately 0.8% of Gulf International Bank UK Ltd's investment portfolio, making the stock its 20th largest holding. Gulf International Bank UK Ltd's holdings in Johnson & Johnson were worth $22,912,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $49,000. Capital A Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $50,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $52,000. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Stock Up 1.2%
Shares of JNJ traded up $2.04 during mid-day trading on Friday, reaching $176.76. The company's stock had a trading volume of 9,457,828 shares, compared to its average volume of 9,041,812. The company's 50 day moving average is $160.85 and its 200 day moving average is $158.16. The stock has a market cap of $425.70 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 2.22 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $177.27.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.82 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on JNJ shares. Bank of America upped their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Finally, UBS Group upped their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $174.50.
Get Our Latest Stock Analysis on JNJ
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access